Lucid Diagnostics Inc. (LUCD): Price and Financial Metrics
LUCD Price/Volume Stats
| Current price | $1.46 | 52-week high | $2.36 |
| Prev. close | $1.43 | 52-week low | $1.11 |
| Day low | $1.40 | Volume | 79,102 |
| Day high | $1.53 | Avg. volume | 69,878 |
| 50-day MA | $1.47 | Dividend yield | N/A |
| 200-day MA | $1.46 | Market Cap | 63.36M |
LUCD Stock Price Chart Interactive Chart >
LUCD Stock Summary
- LUCID DIAGNOSTICS INC's stock had its IPO on October 14, 2021, making it an older stock than only 3.18% of US equities in our set.
- With a price/sales ratio of 79.4, LUCID DIAGNOSTICS INC has a higher such ratio than 97.55% of stocks in our set.
- With a year-over-year growth in debt of 546.2%, LUCID DIAGNOSTICS INC's debt growth rate surpasses 97.68% of about US stocks.
- Stocks that are quantitatively similar to LUCD, based on their financial statements, market capitalization, and price volatility, are VCEL, CSTL, AYX, BSGM, and HIPO.
- To check out LUCID DIAGNOSTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001799011.
LUCD Valuation Summary
- LUCD's price/sales ratio is 79.4; this is 4078.95% higher than that of the median Healthcare stock.
- LUCD's price/earnings ratio has moved up 51.4 over the prior 24 months.
Below are key valuation metrics over time for LUCD.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LUCD | 2023-09-22 | 79.4 | 4.2 | -1.1 | -0.8 |
| LUCD | 2023-09-21 | 79.4 | 4.2 | -1.1 | -0.8 |
| LUCD | 2023-09-20 | 79.9 | 4.2 | -1.1 | -0.8 |
| LUCD | 2023-09-19 | 84.4 | 4.4 | -1.2 | -0.8 |
| LUCD | 2023-09-18 | 82.7 | 4.4 | -1.2 | -0.8 |
| LUCD | 2023-09-15 | 83.9 | 4.4 | -1.2 | -0.8 |
Lucid Diagnostics Inc. (LUCD) Company Bio
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest LUCD News From Around the Web
Below are the latest news stories about LUCID DIAGNOSTICS INC that investors may wish to consider to help them evaluate LUCD as an investment opportunity.
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare ConferencePAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, today announced their participation in the 2023 Cantor Fitzgerald Global Healthcare Conference in New York City. |
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer DetectionLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced it has released positive interim data from the multicenter, CLinical Utility of EsoGuard (CLUE) study. This is the Company's first report of prospective data from multiple physicians demonstrating real-world clinical utility of EsoGuard® Esophageal DNA testing for the det |
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire FightersLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced it has released positive data from a retrospective analysis demonstrating real-world clinical utility of EsoGuard® Esophageal DNA testing for the detection of esophageal precancer in a large cohort of fire fighters. |
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee BenefitLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that the Company has contracted with the Ancira Auto Group ("Ancira"), a premier auto dealer serving South Texas, to offer EsoGuard® esophageal precancer testing to eligible employees across all twelve of its locations in San Antonio and surrounding areas. This represents Lucid's first such |
Q2 2023 Lucid Diagnostics Inc Earnings CallQ2 2023 Lucid Diagnostics Inc Earnings Call |
LUCD Price Returns
| 1-mo | -1.35% |
| 3-mo | 5.04% |
| 6-mo | 5.04% |
| 1-year | -8.18% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 7.35% |
| 2022 | -74.67% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...